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Introduction
Cryopyrin-associated periodic syndrome (CAPS) is a rare
systemic, monogenetic inherited autoinflammatory condi-
tion caused by NLRP3/CIAS 1 gene mutations encoding
for cryopyrin, a major component of the inflammasome,
leading to an excessive production of interleukin-1beta
(IL-1ß). The clinical picture of genetic variations of the
NLRP3 inflammasome is characterized by recurrent epi-
sodes of systemic inflammation involving skin, joints, eyes
and the central nervous system and shows variable pene-
trance regarding disease severity and symptoms.
Case Report
Here, we report an unusual case of a 43 year-old woman
who presented to us with diagnosis of CRION (chronic
relapsing inflammatory optic neuropathy) due to recurrent
episodes of optic neuritis on both eyes leading to atrophy
of the left optical nerve with blindness. Repeated cerebral
MRI scan showed an unusual excessive contrast enhance-
ment involving both optic nerves with massive swelling as
well as contrast enhancement in the oculomotor nerve
and the pituitary gland. Additionally a few unspecific
hyperintense white matter lesions were seen. Examination
of the cerebrospinal fluid (CSF) revealed a mild pleocytosis
and oligoclonal bands. Extensive laboratory investigations
for other inflammatory CNS diseases as well as rheumato-
logical diseases remained all unremarkable. Treatment
with high dose i.v. steroids improved visual acuity, but
worsened again after cessation of steroid therapy.
Furthermore the patient reported about intermittent
tendinitis and tension type headache. Laboratory examina-
tions revealed recurrent increased levels of Serum Amy-
loid A (SAA) and C-reactive protein (CRP). Molecular
genetic testing showed a homozygous Q703K mutation in
Exon 3 of the NLRP3/CIAS 1 gene. Diagnosis of CAPS
was set and high dose anti-Interleukin 1 therapy initiated
which led so far to moderate improvement of the CNS
inflammation as well as reduction of SAA levels. The
patient is currently followed up.
Discussion
This is an unusual and severe CNS manifestation in a
patient homozygous for the Q703K variant in exon 3 of
the NLRP3/CIAS 1 gene which has been considered so far
as a low-penetrance mutation with a mild phenotype.
Ocular manifestations including optic nerve atrophy
usually occur in classical CICNA/NOMID patients. This
case illustrates that CAPS should be also considered in
adult patients with chronic recurrent optic neuritis and
additional symptoms suggestive of an autoinflammatory
syndrome.
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